Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study

Momenta Pharmaceuticals, Inc.0 个研究点目标入组 90 人开始时间: 2019年9月17日最近更新: 2021年4月5日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Momenta Pharmaceuticals, Inc.
入组人数: 90

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Inclusion Criteria -
•1. Male or female =18 years of age.
•2. Diagnosed with active primary or secondary wAIHA, defined as having
•all of the following:
•a.Hemoglobin level <9 g/dL or <10 g/dL if symptomatic or on
•corticosteroids/immunosuppressants AND
•b.Signs of hemolysis, defined as: lactate dehydrogenase (LDH) levels
•above the upper limit of normal (ULN), or haptoglobin below the lower
•limit of normal, or total bilirubin above the ULN AND
•c.Serological evidence of anti-erythrocyte antibodies associated with a
•positive DAT that is either positive for IgG only or is positive for IgG and
•C3d (fragment of the third component of complement) at time of
•3.Has been diagnosed with wAIHA for at least 3 months, has received
•standard of care treatment for wAIHA but is not currently under
•adequate control
•4.If on corticosteroids, are on a dose that has been stable for at least 14
•days prior to randomization.
•5.If currently receiving immunosuppressants, has been on a stable dose
•for 30 days prior to Screening. Allowed concomitant
•immunosuppressants are azathioprine, mycophenolate
•mofetil/mycophenolic acid, cyclosporine, cyclophosphamide.
•6.Have a platelet count =30 × 109/L.
•7.Have screening serum albumin and serum calcium concentrations
•within the normal range.
•8.Have screening total serum IgG of at least 600 mg/dL.
•9.Have a screening creatine kinase (CK) value <2 × ULN.
•10.Have a negative QuantiFERON®-TB Gold test.
•11.Patients who have undergone splenectomy must be at least 3 months
•post resection prior to screening and must be vaccinated as per the
•United States Center for Disease Control and Prevention (CDC) annual
•Recommended Immunization Schedule for Adults Aged 19 Years or
•Older, United States
•12.Patients with autoimmune disease (eg, systemic lupus erythematosus
•or rheumatoid arthritis) and lymphoproliferative disorders may be
•eligible if they are stable (no changes in concomitant disease-related
•medications and severity of disease for at least 3 months). Patients with
•lymphoproliferative disease must have a low grade, be stable and be, in
•the opinion of the Investigator, unlikely to require chemotherapy or
•monoclonal antibody therapy during the study. Patients requiring change
•of treatment or new treatment (but not rescue therapy) during the study
•will be terminated from the study
•13.Have sufficient venous access to allow drug administration by IV
•infusion and blood sampling as per the protocol.
•14.Women of childbearing potential (WOCBP), defined as women
•physiologically capable of becoming pregnant, must have a negative
•serum pregnancy test at screening and a negative urine pregnancy test
•at Baseline. Menopausal women must have an elevated serum folliclestimulating
•hormone (FSH) level at Screening; if the FSH is not elevated,
•they are considered to be of childbearing potential and must have a
•negative serum pregnancy test at screening and a negative urine
另有 8 项未显示

排除标准

•Exclusion Criteria -
•1.Have received a transfusion within 30 days prior to randomization.
•2.Have any other associated cause of hereditary or acquired hemolytic
•3.Have received rituximab within 6 months prior to randomization.
•Note: Patients who received rituximab within 3 months but have
•evidence of worsening hemolysis (defined as LDH levels above ULN or
•haptoglobin levels below the lower limit of the normal range (LLN) or
•total bilirubin levels above the ULN) may be included in the study.
•4. Has received IVIG within 6 weeks prior to randomization on Day 1. The patient may be
•re-screened after the exclusionary period of 6 weeks has passed.
•5.Have cold antibody AIHA, cold agglutinin syndrome, mixed type (ie,
•warm and cold) AIHA, or paroxysmal cold hemoglobinuria.
•6.Have a severe infection (eg, pneumonia, biliary tract infection,
•diverticulitis, Clostridium difficile infection) that requires parenteral
•anti-infectives and/or hospitalization, and/or is assessed as
•serious/clinically significant by the Investigator, within 8 weeks prior to
•screening. The patient may be re-screened after the 8 week exclusionary
•period has passed. Any patient with an infection requiring oral antiinfectives
•(eg, sinusitis, bronchitis, uncomplicated urinary tract
•infection) within 4 weeks prior to screening will be excluded, but may be
•subsequently re-screened after the 4 week exclusionary period has
•7.Have a chronic infection (eg, bronchiectasis, chronic osteomyelitis,
•chronic pyelonephritis) or require chronic treatment with anti-infectives
•(eg, antibiotics, antivirals).
•8.Have received a live vaccine within 3 months prior to screening, or
•have a known need to receive a live vaccine during the study or within at
•least 3 months after the last dose of study drug. The patient may be re
•screened after the 3 month exclusionary period has ended.
•9. Has any confirmed or suspected clinical immunodeficiency syndrome not related to
•treatment of his/her wAIHA, or has a family history of congenital or hereditary
•immunodeficiency unless confirmed absent in the patient.
•10.Have a known history of, or positive test result for human
•immunodeficiency virus-1 (HIV 1) and HIV 2 antibodies, hepatitis B virus
•(HBV core antigen), or hepatitis C virus (HCV).
•Note: Patients with past HCV may be included in the study if they have a
•documented negative HCV ribonucleic acid level in the serum at 12
•weeks or longer after the completion of HCV therapy.
•11.Are currently breastfeeding, pregnant, intend to become pregnant
•during the study, or are planning egg donation during the study or
•within 30 days after the last dose of study drug.
•12.Have current alcohol/substance abuse/dependence, a history of
•alcohol/substance abuse/dependence within the 12 months prior to
•screening, or, in the Investigator's opinion, show evidence of ongoing
•alcohol/substance abuse/dependence.
•13.Are currently participating in another interventional clinical trial or
•have received any investigational drug within the past 3 months.
•14.Have had any major surgery within 3 months prior to screening or
•have plans for or have been scheduled for any elective surgery or major
•dental procedure during the study.
•15.Have a history of a major organ transplant (eg, heart, lung, kidney,
另有 3 项未显示

研究者

发起方

Momenta Pharmaceuticals, Inc.

相似试验

招募中

2 期

Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study with a Long-term Open-label ExtensioWarm Autoimmune Hemolytic AnemiawAIHA1001891110003816

NL-OMON54686Janssen-Cilag International NV6

进行中（未招募）

1 期

Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study with a Long-term Open-label ExtensioMedDRA version: 20.0Level: LLTClassification code: 10073784Term: Anemia hemolytic autoimmune Class: 10005329Warm Autoimmune Hemolytic Anemia

CTIS2023-505321-14-00Janssen - Cilag International111

进行中（未招募）

1 期

Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic AnemiaAdults with Warm Autoimmune Hemolytic AnemiaMedDRA version: 20.1Level: LLTClassification code 10002285Term: Anemia hemolytic autoimmune (NOS)System Organ Class: 100000004851

EUCTR2019-000720-17-GRJanssen-Cilag International NV148

进行中（未招募）

1 期

Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia

EUCTR2019-000720-17-CZJanssen-Cilag International NV148

进行中（未招募）

1 期

EUCTR2019-000720-17-NLJanssen-Cilag International NV148